Pepvise
Compound profile· Compounds

Selank, what the evidence shows

By The PepVise Editorial Team · Reviewed July 2, 2026 · 13 min read

Evidence Ledger for selank: a synthetic analog of the endogenous peptide tuftsin used clinically in Russia as an anxiolytic, with a literature base that is largely Russian-language and thin on independent replication outside Russia.

We describe what has been measured, by whom, at what scale, with what effect size, and with what caveats. Hedging, here, is honesty.
The PepVise Editorial Teamfrom the house style guide
Editorial reference
Primary literature

PubMed saved search, 'selank'

Selank, like its sister peptide semax, is a compound where the honest starting point is the search itself, because it surfaces how much of the literature is Russian-language and how little is independently replicated outside Russia. A saved search shows the reader the evidence concentration directly, which is more useful than any blog summary, including ours.

Reference reading

The texts we read alongside the papers.

  1. 01
    Primary literature

    PubMed saved search, 'selank'

    A PubMed search for 'selank' returns a body of work dominated by Russian research groups, much of it translated abstracts of Russian-language papers. It is the fastest way to see the defining feature of the evidence base: geographic and linguistic concentration, with limited independent replication in non-Russian labs. The same pattern applies to semax.

  2. 02
    Reference text

    Williams Textbook of Endocrinology (14th ed.)

    Selank is a synthetic analog of tuftsin, an immunomodulatory peptide fragment, and the immune and neuropeptide physiology it is built on is standard science. Williams provides that background without the nootropic-marketing layer that vendor and forum pages add. Read it for the peptide biology, not for any use guidance.

  3. 03
    Popular-science background

    Outlive, Peter Attia, MD (with Bill Gifford)

    Attia's framework for separating a mechanistic or surrogate finding from a hard clinical outcome applies directly to selank, whose strongest claims rest on a literature that is hard for an outside reader to scrutinize. It does not cover selank; the reasoning discipline is the point.

Methodology

How we read the literature

Evidence tier
We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
Trial stage
Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
Regulatory status
We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
Where we're uncertain
Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.
Frequently asked

The questions readers actually bring us.

Is selank FDA-approved?
No. Selank has no FDA-approved indication. It is registered as a drug in Russia and used there for indications including generalized anxiety disorder, but that registration does not apply outside Russia. In the US and EU it circulates as a research chemical labeled for non-human use.
How strong is the evidence for selank?
Geographically concentrated and hard to scrutinize independently. Most of the clinical and preclinical literature comes from Russian research groups and is published in Russian-language journals with limited international indexing. Independent replication by unaffiliated labs outside Russia is the central open question, the same limitation that applies to semax.
What is selank supposed to do?
It is a synthetic analog of tuftsin described as an anxiolytic and neuroactive peptide, given intranasally in Russia. Its proposed mechanism centers on GABAergic and monoaminergic modulation and effects on BDNF, with preclinical support in rodent models. A coherent mechanism in animals is not the same as a replicated clinical benefit in humans.
How is selank different from semax?
They are sister peptides: both Russian-developed, both stabilized with a proline-glycine-proline tail, both given intranasally, both registered in Russia and unapproved elsewhere. Semax derives from an ACTH fragment and is framed around cognition and stroke recovery; selank derives from tuftsin and is framed around anxiety. Both share the same evidence limitation, a literature concentrated in Russian-language sources.
Why does PepVise not give a selank dose?
Because we describe the literature and do not recommend administration. The doses repeated online come from Russian protocols and forums, not from internationally replicated dose-finding trials. We explain how these research chemicals are regulated separately.
What would change our reading

A Phase 2 randomized trial with blinded outcome assessment would change the reading. A new independent replication outside the currently dominant research group would change the reading. A regulatory action, approval, restriction, or a class warning, would change the reading. When any of those lands, we update this profile within a week and mark what changed.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Further reading

Adjacent in the literature.

Compounds · Compound profile

BPC-157, What the Evidence Shows

Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.

16 min readCompounds · Compound profile

TB-500, The Field Guide

TB-500 vs Thymosin Beta-4 (same compound), mechanism, the preclinical tendon and recovery literature, and where the human data is thin.

14 min readCompounds · Compound profile

GHK-Cu, Evidence and Hype

Copper peptide signaling, the topical RCT evidence for hair and skin, and the gap between topical and injectable claims.

13 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.